Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Gulo who wrote (24)	11/1/2000 10:48:18 AM
From: Gulo	Respond to of 103

Correction: Moving on to the stage where patients are injected concurrently means they have completed the first six patients (not just three). "Patient #1 in cohort #1 receives 1 injection and the safety results from this patient are assessed after being monitored for 2 to 3 weeks. Patient #2 of cohort #1 receives their injection once the patient #1 assessment indicates progression to the next patient is appropriate. This procedure is expected to continue through the first two cohorts. Once these cohorts are completed and show no significant safety concerns, the subsequent cohorts are expected to receive their injections concurrently. " -g